Clinical Experience with Multilamellar Liposomal Amphotericin B in Patients with Proven and Suspected Fungal Infections

References

• Lopez-Berestein G, Fainstein V, Hopfer R L, Mehta K, Sullivan M P, Keating M, Rosenblum M G, Mehta R, Luna M, Hersh E M, Reuben J, Juliano R L, Bodey G P. Liposomal amphotericin B for treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1984; 151: 704–710
   Web of Science ®Google Scholar
• Chopra R, Blair S, Strang J, Cervi P, Patterson K G, Goldstone A H. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991; 28(Suppl. B)93–104
   PubMedGoogle Scholar
• Coker R J, Murphy S M, Harris J RW. Experience with liposomal amphotericin (AmBisome) in cryptococcal meningitis in AIDS. J Antimicrob Chemother 1991; 28(Suppl. B)105–109
   PubMedGoogle Scholar
• Davidson R N, Croft S L, Scott A, Maini M, Moody A H, Bryceson A DM. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991; 337: 1061–1062
   PubMed Web of Science ®Google Scholar
• Galbraith J, Preiksaitis J K, Czekanski S, Poznansky M J, Hirji M. Successful management of sequential pulmonary infections in a cardiac transplant patient. Can J Infect Dis 1990; 1: 85–91
   PubMedGoogle Scholar
• Kan V L, Bennett J E, Amantea M A, Smolskis M C, McManus E, Grasela D M, Sherman J W. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J Infect Dis 1991; 164: 418–421
   PubMed Web of Science ®Google Scholar
• Katz N M, Pearce P F, Anzeck R A, Visner M S, Canter H G, Foegh M L, Pearle D L, Tracy C, Rahman A. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant 1990; 9: 14–17
   PubMedGoogle Scholar
• Levine S J, Walsh T J, Martinez A, Eichacker P Q, Lopez-Berestein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991; 114: 664–666
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G, Bodey G P, Frankel L S, Mehta K. Treatment of hepatosplenic candidiasis with liposomal amphotericin B. J Clin Oncol 1987; 5: 310–317
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G, Bodey G P, Fainstein V, Keating M, Frankel L S, Zeluff B, Gentry L, Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989; 149: 2533–2536
   PubMed Web of Science ®Google Scholar
• Meunier F, Sculier J P, Coune A, Brassine C, Heyman C, Laduron C, Collette N, Hollaert C, Bron D, Klastersky J. Amphotericin B encapsulated in liposomes administered to cancer patients. Ann NY Acad Sci 1988; 544: 598–610
   PubMedGoogle Scholar
• Ralph E D, Barber K R, Grant C WM. Liposomal amphotericin B: an effective, nontoxic preparation for the treatment of urinary tract infections caused by Candida albicans. Am J Nephrol 1991; 11: 118–122
   PubMedGoogle Scholar
• Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani M A, Gorin N C, Klastersky J, Fenaux P, Prentice H G, Ksionski G. Efficacy of amphotericin B encapsulated in liposomes (AmBi-some) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(Suppl B)73–82
   PubMed Web of Science ®Google Scholar
• Sanders S W, Buchi K N, Goddard M S, Lang J K, Tolman K G. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991; 35: 1029–1034
   PubMed Web of Science ®Google Scholar
• Schurmann D, Marques B M, Grunewald T, Pohle H D, Hahn H, Ruf B. Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated Cryptococcosis. J Infect Dis 1991; 164: 620–622
   PubMed Web of Science ®Google Scholar
• Sculier J P, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 1988; 24: 527–538
   PubMedGoogle Scholar
• Sculier J P, Bron D, Coune A, Meunier F. Successful treatment with amphotericin B in two patients with persisting fungemia. Eur J Clin Microbiol Infect Dis 1989; 8: 903–907
   PubMed Web of Science ®Google Scholar
• Smith O P, Prentice H G. Liposomal amphotericin B and erythrocyte echinocytosis. Bone Marrow Transplant 1991; 8: 155–157
   PubMedGoogle Scholar
• Weber R S, Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal amphotericin B. Laryngoscope 1987; 97: 937–941
   PubMed Web of Science ®Google Scholar
• Grant C WM, Hamilton K S, Hamilton K D, Barber K R. Physical biochemistry of a liposomal amphotericin B mixture used for patient treatment. Biochim Biophys Acta 1989; 984: 11–20
   PubMed Web of Science ®Google Scholar
• Janoff A S, Boni L T, Popescu M C, Minchey S R, Cullis P R, Madden T D, Taraschi T, Gruner S M, Shyamsunder E, Tate M W, Mendelsohn R, Bonner D. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci 1988; 85: 6122–6126
   PubMed Web of Science ®Google Scholar
• Longuet P, Joly V, Amirault P, Seta N, Carbon C, Yeni P. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusion in rats. Antimicrob Agents Chemother 1991; 35: 1303–1308
   PubMed Web of Science ®Google Scholar
• Clark J M, Whitney R R, Olsen S J, George R J, Swerdel M R, Kunselman L, Bonner D P. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35: 615–621
   PubMed Web of Science ®Google Scholar
• Gondal J A, Swartz R P, Rahman A. Therapeutic evaluation of free and liposomal encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 1989; 33: 1544–1548
   PubMed Web of Science ®Google Scholar
• Graybill J R, Craven P C, Taylor R L, Williams D M, Magee W E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982; 145: 748–752
   PubMed Web of Science ®Google Scholar
• Juliano R L, Grant C WM, Barber K R, Kalp M A. Mechanism of selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987; 31: 1–11
   PubMed Web of Science ®Google Scholar
• Jullien S, Contrepois A, Sligh J E, Domart Y, Yeni P, Brajtburg J, Medoff G, Bolard J. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob Agents Chemother 1989; 33: 345–349
   PubMed Web of Science ®Google Scholar
• Jullien S, Brajtburg J, Bolard J. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim Biophys Acta 1990; 1021: 39–45
   PubMed Web of Science ®Google Scholar
• Ralph E D, Khazindar A M, Barber K R, Grant C WM. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother 1991; 35: 188–191
   PubMedGoogle Scholar
• Tremblay C, Barza M, Fiore C, Szoka F. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 1984; 26: 170–173
   PubMed Web of Science ®Google Scholar
• Wasan K M, Vadiei K, Lopez-Berestein G, Luke D R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis 1990; 161: 562–566
   PubMed Web of Science ®Google Scholar
• Brajtburg J, Powderly W G, Kobayashi G, Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother 1990; 34: 381–384
   PubMed Web of Science ®Google Scholar
• Patterson T F, Andriole V T. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol Suppl 1989; 2: S63–S68
   Google Scholar
• Zonneveld G M, Crommelin D JA. Liposomes: parenteral administration to man. Liposomes as drug carriers, G Gregoriadis. Wiley & Sons, New York 1988; 795–817
   Google Scholar
• Hamilton K S, Barber K R, Davis J H, Neil K, Grant C WM. Phase behaviour of amphotericin B multilamellar vesicles. Biochim Biophys Acta 1991; 1062: 220–226
   PubMedGoogle Scholar
• Kennedy M S, Deeg H J, Siegel M, Crowley J J, Storb R, Thomas E D. Acute renal toxicity with combined use of amphotericin B and cyclosporin after marrow transplantation. Transplantation 1983; 35: 211–215
   PubMed Web of Science ®Google Scholar
• Fielding R M, Singer A W, Wang L H, Babbar S, Guo L S. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992; 36: 299–307
   PubMed Web of Science ®Google Scholar
• Bolard J. Mechanism of action of an anti-Candida drug: amphotericin B and its derivatives. Candida albicans, R Prasad. Springer-Verlag, Berlin, Heidelberg 1991
   Google Scholar
• Meunier F, Prentice H G, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother Suppl. B 1991; 83–91
   PubMedGoogle Scholar